Inhibition of prolyl oligopeptidase by KYP-2047 fails to increase the extracellular neurotensin and substance P levels in rat striatum

Neuroscience Letters

Volumn 502, Issue 2, 2011, Pages 107-111

  Jalkanen, Aaro J ^a   Savolainen, Katja ^a   Forsberg, Markus M ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Microdialysis; Neurotensin; Prolyl oligopeptidase; Radioimmunoassay; Substance P

Indexed keywords

4 PHENYLBUTANOYL L PROLYL CYANOPYRROLIDINE; BUPRENORPHINE; N BENZYL 2 [[2 (HYDROXYACETYL) 1 PYRROLIDINYL]CARBONYL] 1 PYRROLIDINECARBOXAMIDE; NEUROKININ B; NEUROTENSIN; PHYSALAEMIN; PROLINE CARBOXYPEPTIDASE; PROLYL ENDOPEPTIDASE; SERINE PROTEINASE INHIBITOR; SOMATOSTATIN; SUBSTANCE P; UNCLASSIFIED DRUG;

ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORPUS STRIATUM; CROSS REACTION; DRUG SYNTHESIS; DRUG TARGETING; ENZYME REGULATION; EXTRACELLULAR SPACE; MALE; MAXIMUM PLASMA CONCENTRATION; MICRODIALYSIS; NONHUMAN; PARENCHYMA; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PROTEIN PROCESSING; RADIOIMMUNOASSAY; RAT; SINGLE DRUG DOSE;

ANIMALS; CORPUS STRIATUM; EXTRACELLULAR SPACE; MALE; MICRODIALYSIS; NEUROTENSIN; PROLINE; RADIOIMMUNOASSAY; RATS; RATS, WISTAR; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; SUBSTANCE P;

EID: 80051808482     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.07.033     Document Type: Article

References (38)

1. Bellemere G., Morain P., Vaudry H., Jegou S. Effect of S 17092, a novel prolyl endopeptidase inhibitor, on substance P and alpha-melanocyte-stimulating hormone breakdown in the rat brain. J. Neurochem. 2003, 84(5):919-929.
2. Benveniste H., Hüttemeier P.C. Microdialysis: theory and application. Prog. Neurobiol. 1990, 5(3):195-215.
3. Brandt I., De Vriendt K., Devreese B., Van Beeumen J., Van Dongen W., Augustyns K., De Meester I., Scharpe S., Lambeir A.M. Search for substrates for prolyl oligopeptidase in porcine brain. Peptides 2005, 26(12):2536-2546.
4. Brandt I., Gerard M., Sergeant K., Devreese B., Baekelandt V., Augustyns K., Scharpe S., Engelborghs Y., Lambeir A.M. Prolyl oligopeptidase stimulates the aggregation of alpha-synuclein. Peptides 2008, 29(9):1472-1478.
5. Chaurasia C.S., Müller M., Bashaw E.D., Benfeldt E., Bolinder J., Bullock R., Bungay P.M., DeLange E.C., Derendorf H., Elmquist W.F., Hammarlund-Udenaes M., Joukhadar C., Kellogg D.L., Lunte C.E., Nordström C.H., Rollema H., Sawchuk R.J., Cheung B.W., Shah V.P., Ståhle L., Ungerstedt U., Welty D.F., Yeo H. AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives. Pharm. Res. 2007, 24(5):1014-1025.
6. Cunningham D.F., O'Connor B. Proline specific peptidases. Biochim. Biophys. Acta 1997, 1343(2):160-186.
7. Di Daniel E., Glover C.P., Grot E., Chan M.K., Sanderson T.H., White J.H., Ellis C.L., Gallagher K.T., Uney J., Thomas J., Maycox P.R., Mudge A.W. Prolyl oligopeptidase binds to GAP-43 and functions without its peptidase activity. Mol. Cell. Neurosci. 2009, 41(3):373-382.
8. Gaggar A., Jackson P.L., Noerager B.D., O'Reilly P.J., McQuaid D.B., Rowe S.M., Clancy J.P., Blalock J.E. A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation. J. Immunol. 2008, 180(8):5662-5669.
9. Harrison S., Geppetti P. Substance P. Int. J. Biochem. Cell Biol. 2001, 33(6):555-576.
10. Huston J.P., Hasenohrl R.U. The role of neuropeptides in learning: focus on the neurokinin substance P. Behav. Brain Res. 1995, 66(1-2):117-127.
11. A.J. Jalkanen, J.J. Hakkarainen, M. Lehtonen, T. Venäläinen, T.M. Kääriäinen, E.M. Jarho, M. Suhonen, M.M. Forsberg, Brain pharmacokinetics of two prolyl oligopetidase inhibitors, JTP-4819 and KYP-2047, in the rat, Basic Clin. Pharmacol. Toxicol., in press. doi:10.1111/j.1742-7843.2011.00747.x.
12. Jalkanen A.J., Puttonen K.A., Venäläinen J.I., Sinervä V., Mannila A., Ruotsalainen S., Jarho E.M., Wallen E.A., Männistö P.T. Beneficial effect of prolyl oligopeptidase inhibition on spatial memory in young but not in old scopolamine-treated rats. Basic Clin. Pharmacol. Toxicol. 2007, 100(2):132-138.
13. Jarho E.M., Venäläinen J.I., Huuskonen J., Christiaans J.A., Garcia-Horsman J.A., Forsberg M.M., Järvinen T., Gynther J., Männistö P.T., Wallen E.A. A cyclopent-2-enecarbonyl group mimics proline at the P2 position of prolyl oligopeptidase inhibitors. J. Med. Chem. 2004, 47(23):5605-5607.
14. Jin G., Cheng Q., Feng J., Li F. On-line microdialysis coupled to analytical systems. J. Chromatogr. Sci. 2008, 46(3):276-287.
15. Kovacs G.L., De Wied D. Peptidergic modulation of learning and memory processes. Pharmacol. Rev. 1994, 46(3):269-291.
16. Lee J.W., Devanarayan V., Barrett Y.C., Weiner R., Allinson J., Fountain S., Keller S., Weinryb I., Green M., Duan L., Rogers J.A., Millham R., O'Brien P.J., Sailstad J., Khan M., Ray C., Wagner J.A. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res. 2006, 23(2):312-328.
17. Männistö P.T., Venäläinen J., Jalkanen A., Garcia-Horsman J.A. Prolyl oligopeptidase: a potential target for the treatment of cognitive disorders. Drug News Perspect. 2007, 20(5):293-305.
18. Marighetto A., Touzani K., Etchamendy N., Torrea C.C., De Nanteuil G., Guez D., Jaffard R., Morain P. Further evidence for a dissociation between different forms of mnemonic expressions in a mouse model of age-related cognitive decline: effects of tacrine and S 17092, a novel prolyl endopeptidase inhibitor. Learn. Mem. 2000, 7(3):159-169.
19. Morain P., Lestage P., De Nanteuil G., Jochemsen R., Robin J.L., Guez D., Boyer P.A. S 17092: a prolyl endopeptidase inhibitor as a potential therapeutic drug for memory impairment. Preclinical and clinical studies. CNS Drug Rev. 2002, 8(1):31-52.
20. Myöhänen T.T., Venäläinen J.I., Garcia-Horsman J.A., Piltonen M., Männistö P.T. Cellular and subcellular distribution of rat brain prolyl oligopeptidase and its association with specific neuronal neurotransmitters. J. Comp. Neurol. 2008, 507(5):1694-1708.
21. Nolte W.M., Tagore D.M., Lane W.S., Saghatelian A. Peptidomics of prolyl endopeptidase in the central nervous system. Biochemistry 2009, 48(50):11971-11981.
22. Re R.N., Cook J.L. The intracrine hypothesis: an update. Regul. Pept. 2006, 133(1-3):1-9.
23. Ribeiro-da-Silva A., Hökfelt T. Neuroanatomical localisation of substance P in the CNS and sensory neurons. Neuropeptides 2000, 34(5):256-271.
24. Schulz I., Zeitschel U., Rudolph T., Ruiz-Carrillo D., Rahfeld J.U., Gerhartz B., Bigl V., Demuth H.U., Rossner S. Subcellular localization suggests novel functions for prolyl endopeptidase in protein secretion. J. Neurochem. 2005, 94(4):970-979.
25. Shinoda M., Matsuo A., Toide K. Pharmacological studies of a novel prolyl endopeptidase inhibitor, JTP-4819, in rats with middle cerebral artery occlusion. Eur. J. Pharmacol. 1996, 305(1-3):31-38.
26. Shinoda M., Miyazaki A., Toide K. Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on spatial memory and on cholinergic and peptidergic neurons in rats with ibotenate-induced lesions of the nucleus basalis magnocellularis. Behav. Brain Res. 1999, 99(1):17-25.
27. St-Gelais F., Jomphe C., Trudeau L.E. The role of neurotensin in central nervous system pathophysiology: what is the evidence?. J. Psychiat. Neurosci. 2006, 31(4):229-245.
28. Szeltner Z., Morawski M., Juhasz T., Szamosi I., Liliom K., Csizmok V., Tolgyesi F., Polgar L. GAP43 shows partial co-localisation but no strong physical interaction with prolyl oligopeptidase. Biochim. Biophys. Acta 2010, 1804(12):2162-2176.
29. Tenorio-Laranga J., Valero M.L., Männistö P.T., Sanchez del Pino M., Garcia-Horsman J.A. Combination of snap freezing, differential pH two-dimensional reverse-phase high-performance liquid chromatography, and iTRAQ technology for the peptidomic analysis of the effect of prolyl oligopeptidase inhibition in the rat brain. Anal. Biochem. 2009, 393(1):80-87.
30. Tenorio-Laranga J., Venäläinen J.I., Männistö P.T., Garcia-Horsman J.A. Characterization of membrane-bound prolyl endopeptidase from brain. FEBS J. 2008, 275(17):4415-4427.
31. Toide K., Fujiwara T., Iwamoto Y., Shinoda M., Okamiya K., Kato T. Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on neuropeptide metabolism in the rat brain. Naunyn Schmiedebergs Arch. Pharmacol. 1996, 353(3):355-362.
32. Toide K., Iwamoto Y., Fujiwara T., Abe H. JTP-4819: a novel prolyl endopeptidase inhibitor with potential as a cognitive enhancer. J. Pharmacol. Exp. Ther. 1995, 274(3):1370-1378.
33. Toide K., Okamiya K., Iwamoto Y., Kato T. Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on prolyl endopeptidase activity and substance P- and arginine-vasopressin-like immunoreactivity in the brains of aged rats. J. Neurochem. 1995, 65(1):234-240.
34. Toide K., Shinoda M., Fujiwara T., Iwamoto Y. Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on spatial memory and central cholinergic neurons in aged rats. Pharmacol. Biochem. Behav. 1997, 56(3):427-434.
35. Toy-Miou-Leong M., Bachelet C.M., Pelaprat D., Rostene W., Forgez P. NT agonist regulates expression of nuclear high-affinity neurotensin receptors. J. Histochem. Cytochem. 2004, 52(3):335-345.
36. Venäläinen J.I., Garcia-Horsman J.A., Forsberg M.M., Jalkanen A., Wallen E.A., Jarho E.M., Christiaans J.A., Gynther J., Männistö P.T. Binding kinetics and duration of in vivo action of novel prolyl oligopeptidase inhibitors. Biochem. Pharmacol. 2006, 71(5):683-692.
37. Williams R.S., Cheng L., Mudge A.W., Harwood A.J. A common mechanism of action for three mood-stabilizing drugs. Nature 2002, 417(6886):292-295.
38. Williams R.S., Eames M., Ryves W.J., Viggars J., Harwood A.J. Loss of a prolyl oligopeptidase confers resistance to lithium by elevation of inositol(1,4,5)trisphosphate. EMBO J. 1999, 18(10):2734-2745.